Strongbridge Biopharma Profile

USD 0.25  3.68%

Acquisition by Cohen Fredric J of 116000 shares of Strongbridge Biopharma subject to Rule 16b-3

Strongbridge Biopharma plc insider trading alert for grant of employee stock option (right to buy) by Cohen Fredric J, Chief Medical Officer, on February 6, 2018. This event was filed by Strongbridge Biopharma Pl with SEC on 2018-02-06. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Strongbridge Biopharma Summary

Strongbridge Biopharma plc (SBBP) is traded on NASDAQ in USA. It is located in PENNSYLVANIA, U.S.A and employs 24 people. Strongbridge Biopharma is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 276.7 M. Strongbridge Biopharma plc has 39.81 M outstanding shares of which 812.36 K shares are at this time shorted by private and institutional investors with about 5.96 trading days to cover. Strongbridge Biopharma plc currently holds about 44.37 M in cash with (41.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.24.
Check Strongbridge Biopharma Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Strongbridge Biopharma plc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Strongbridge Biopharma Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 19% 
Equity ratings for Strongbridge Biopharma plc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States, Sweden, and Cayman Islands. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania. Strongbridge Biopharma is traded on NASDAQ in USA. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameStrongbridge Biopharma plc
CEO and President and DirectorMatthew PaulsAll Leadership
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
Business Address900 Northbrook Drive
IndustryPharmaceutical Products
Contact Number610 254 9200
CurrencyUSD - US Dollar


Strongbridge Biopharma Analyst Recommendations
Target PriceAdvice# of Analysts
17.33Strong Buy3Odds
Strongbridge Biopharma plc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Strongbridge Biopharma Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Strongbridge Biopharma Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.32March 23, 2017
Strongbridge Biopharma plc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Strongbridge Biopharma Corporate Directors
Richard Kollender Director
Garheng Kong Director, MBA
Marten Steen Director, Ph.D